epoprostenol
Selected indexed studies
- Epoprostenol for the treatment of pulmonary arterial hypertension. (Expert Rev Clin Pharmacol, 2021) [PMID:34030557]
- Epoprostenol Therapy for Pulmonary Arterial Hypertension. (Acta Med Okayama, 2015) [PMID:26101188]
- Epoprostenol sodium for treatment of pulmonary arterial hypertension. (Vasc Health Risk Manag, 2015) [PMID:25999730]
_Worker-drafted node — pending editorial review._
Connections
epoprostenol is a side effect of
Sources
- Epoprostenol for the treatment of pulmonary arterial hypertension. (2021) pubmed
- Epoprostenol Therapy for Pulmonary Arterial Hypertension. (2015) pubmed
- Epoprostenol sodium for treatment of pulmonary arterial hypertension. (2015) pubmed
- Inhaled epoprostenol. (2003) pubmed
- Epoprostenol in pulmonary arterial hypertension. (2009) pubmed
- Epoprostenol in primary pulmonary hypertension. (1999) pubmed
- Epoprostenol (Veletri®, Caripul®): a review of its use in patients with pulmonary arterial hypertension. (2014) pubmed
- Pharmacokinetic evaluation of continuous intravenous epoprostenol. (2010) pubmed
- A new epoprostenol formulation for the treatment of pulmonary arterial hypertension. (2012) pubmed
- Prostacyclin-analogs. (1985) pubmed